Obesity and cancer: inflammation bridges the two

Ryan Kolb; Fayyaz S Sutterwala; Weizhou Zhang

doi:10.1016/j.coph.2016.07.005

Back

Obesity and cancer: inflammation bridges the two

Journal article

Peer reviewed

Obesity and cancer: inflammation bridges the two

Ryan Kolb, Fayyaz S Sutterwala and Weizhou Zhang

Current opinion in pharmacology, Vol.29, pp.77-89

08/2016

DOI: 10.1016/j.coph.2016.07.005

PMCID: PMC4992602

PMID: 27429211

Files and links (1)

url

http://doi.org/10.1016/j.coph.2016.07.005View

Open Access

Abstract

Obesity is a growing public health problem and affects 35% US adults. Obesity increases the risk of many cancer types and is associated with poor outcomes. Clinical management of cancer patients has been essentially the same between normal weight and obese individuals. Understanding causal mechanisms by which obesity drives cancer initiation and progression is essential for the development of novel precision therapy for obese cancer patients. One caveat is that various mechanisms have been proposed for different cancer types for their progression under obesity. Since obesity is known to have global impact on inflammation, here we will summarize recent literature and discuss the potential of inflammation being the common causal mechanism to promote cancer promotion across cancer types.

Inflammation - pathology

United States - epidemiology

Body Weight

Obesity - complications

Obesity - immunology

Humans

Inflammation - immunology

Disease Progression

Inflammation - complications

Neoplasms - therapy

Animals

Neoplasms - immunology

Obesity - epidemiology

Adult

Neoplasms - pathology

Details

Title: Subtitle: Obesity and cancer: inflammation bridges the two
Creators: Ryan Kolb - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA, USA
Fayyaz S Sutterwala - Division of Infectious Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Weizhou Zhang - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Interdisciplinary Graduate Program in Immunology, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Medical Scientist Training Program, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Free Radical and Radiation Biology Program, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Cancer Genes and Pathway Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA, USA. Electronic address: weizhou-zhang@uiowa.edu
Resource Type: Journal article
Publication Details: Current opinion in pharmacology, Vol.29, pp.77-89
DOI: 10.1016/j.coph.2016.07.005
PMID: 27429211
PMCID: PMC4992602
NLM abbreviation: Curr Opin Pharmacol
ISSN: 1471-4892
eISSN: 1471-4973
Grant note: R00 CA158055 / NCI NIH HHS T32 AI007260 / NIAID NIH HHS R01 CA200673 / NCI NIH HHS
Language: English
Date published: 08/2016
Academic Unit: Radiation Oncology
Record Identifier: 9984083873002771

Metrics

20 Record Views

316 Times Cited - Web of Science